Strides Pharma Science Ltd Upgraded to Buy on Strong Financials and Bullish Technicals

Technical Outlook Strengthens to Bullish

The primary catalyst for the rating upgrade is the marked improvement in Strides Pharma’s technical grade, which has shifted from mildly bullish to bullish. Key technical indicators support this positive momentum. The Moving Average Convergence Divergence (MACD) is bullish on both weekly and monthly charts, signalling sustained upward momentum. Bollinger Bands also reflect bullish trends on weekly and monthly timeframes, indicating price stability within an upward channel.

Daily moving averages confirm this positive trend, reinforcing short-term strength. Dow Theory assessments on weekly and monthly scales are bullish, suggesting that the stock is in a confirmed uptrend. However, some caution is warranted as the Relative Strength Index (RSI) shows a bearish signal on the monthly chart, and the Know Sure Thing (KST) indicator remains mildly bearish on weekly and monthly periods. Despite these mixed signals, the overall technical picture is positive, with the On-Balance Volume (OBV) indicator showing a bullish trend monthly, indicating accumulation by investors.

Strides Pharma’s current price stands at ₹1,236.90, close to its 52-week high of ₹1,260.10, reflecting strong price appreciation. The stock’s day change of 1.39% on 22 September 2026 further underscores positive investor sentiment.

Valuation Remains Attractive Amidst Growth

Strides Pharma’s valuation metrics have improved, supporting the upgrade. The company’s Return on Capital Employed (ROCE) for the half-year period is an impressive 17.96%, with an attractive valuation multiple of 2.8 times Enterprise Value to Capital Employed. This valuation is discounted relative to its peers’ historical averages, signalling potential upside for investors.

The stock’s Price/Earnings to Growth (PEG) ratio stands at a low 0.4, indicating that earnings growth is not fully priced in by the market. Over the past year, the stock has delivered a 42.10% return, outperforming the BSE500 index and the Sensex, which declined by 9.40% and 12.16% respectively over the same period. This outperformance is supported by a 53.4% rise in profits over the last year, highlighting strong earnings momentum.

Robust Financial Trend and Consistent Performance

Financially, Strides Pharma has demonstrated consistent strength. The company has reported positive results for 12 consecutive quarters, with operating profit growing at an annualised rate of 27.28%. Operating cash flow for the year reached a peak of ₹702.52 crores, underscoring strong cash generation capabilities.

Return on Capital Employed (ROCE) for the half-year is at a record 17.96%, while the Debt-to-Equity ratio remains low at 0.57 times, indicating prudent capital structure management. Despite a high Debt to EBITDA ratio of 1.90 times, the company’s ability to service debt remains manageable given its cash flow strength. However, investors should note that 38.1% of promoter shares are pledged, with pledged holdings increasing by 10.83% over the last quarter, which could exert downward pressure in volatile markets.

Long-term sales growth has been moderate, with net sales increasing at an annual rate of 9.20% over the past five years. Return on Equity (ROE) averages 9.60%, reflecting modest profitability per unit of shareholder funds. Nevertheless, the company’s consistent operating performance and cash flow generation provide a solid foundation for future growth.

Strong Quality Metrics Support Upgrade

Strides Pharma’s quality parameters have also improved, contributing to the upgrade. The company’s operating cash flow and ROCE metrics are at historic highs, reflecting operational efficiency and effective capital utilisation. The low debt-equity ratio further enhances the company’s financial stability, while the consistent positive quarterly results demonstrate resilience in a competitive pharmaceutical sector.

Moreover, the company’s long-term stock performance has been exceptional, with a 454.46% return over three years and 360.70% over five years, vastly outperforming the Sensex’s 13.03% and 26.87% returns respectively. This track record of consistent returns reinforces the quality of Strides Pharma’s business model and management execution.

Comparative Market Performance Highlights Strength

Strides Pharma’s stock has consistently outperformed the broader market indices. Over the last week, the stock returned 4.28%, compared to the Sensex’s 0.10%. Monthly returns are even more striking, with Strides Pharma gaining 25.48% while the Sensex declined by 3.46%. Year-to-date, the stock has surged 37.08%, contrasting sharply with the Sensex’s negative 12.16% return.

Over longer horizons, the company’s outperformance is even more pronounced. In the last 10 years, Strides Pharma has delivered a 183.65% return, exceeding the Sensex’s 162.59%. This sustained outperformance is a testament to the company’s strong fundamentals, strategic execution, and favourable industry positioning.

Risks and Considerations

Despite the positive outlook, investors should remain mindful of certain risks. The company’s Debt to EBITDA ratio of 1.90 times indicates a relatively high leverage level, which could constrain financial flexibility in adverse conditions. Additionally, the increase in pledged promoter shares to 38.1% raises concerns about potential stock price pressure in falling markets.

Furthermore, the modest average Return on Equity of 9.60% suggests that profitability per unit of shareholder capital is not exceptionally high, which may limit upside in earnings growth. The slower net sales growth rate of 9.20% annually over five years also points to challenges in accelerating top-line expansion.

Conclusion: Upgrade Justified by Balanced Strengths

The upgrade of Strides Pharma Science Ltd from Hold to Buy is well justified by a combination of improved technical indicators, attractive valuation, strong financial trends, and solid quality metrics. The company’s ability to generate consistent positive quarterly results, maintain healthy cash flows, and outperform market benchmarks supports a bullish investment stance.

While certain risks related to leverage and pledged shares remain, the overall outlook is positive, making Strides Pharma a compelling small-cap opportunity within the Pharmaceuticals & Biotechnology sector. Investors seeking exposure to a fundamentally sound and technically strong stock may find this upgrade a timely signal to consider adding Strides Pharma to their portfolios.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →